Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?

This article discusses the potential use of monoamine oxidase inhibitors (MAOIs) as a dual-action therapy for patients with prostate cancer and comorbid depression. Prostate cancer is a leading cause of cancer-related death among men in the United States, and comorbid depression is associated with worse survival outcomes. The article explores the antiproliferative effects of MAOIs on prostate cancer cells and their potential to reduce resistance to treatment. It also discusses the relationship between depression, castration-resistant prostate cancer (CRPC), and the role of the hypothalamic-pituitary-adrenal (HPA) axis. However, further research is needed to fully understand the potential benefits and mechanisms of MAOIs in this context. [Extracted from the article]